利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

840 条记录 (耗时 0.032 秒)

    LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS
    6.
    发明公开
    LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS 审中-公开
    拉喹莫德FOR患者的复发 - 缓解型多发性硬化（RRMS）HIGH残疾状况于治疗

    公开(公告)号：EP3137092A1

    公开(公告)日：2017-03-08

    申请号：EP15785579.2

    申请日：2015-04-28

    申请人： Teva Pharmaceutical Industries Ltd.

    发明人： KNAPPERTZ, Volker

    IPC分类号： A61K31/765 ,  A61K47/00 ,  C07D215/00

    CPC分类号： A61K31/4704 ,  A61B5/112 ,  A61B5/4082 ,  A61B5/4839 ,  A61J1/00 ,  A61J7/0076 ,  A61K9/0053 ,  A61K31/47 ,  A61K38/215 ,  A61K45/06

    摘要： This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.

    摘要翻译： 本发明提供用于治疗或用于减少诊断与折磨的人类患者卧床劣化的方法复发缓解型多发性硬化（RRMS）和具有高基线残疾评分雅丁到Kurtzke扩展残疾状态量表（EDSS），周期性地包括 给予只能诊断为RRMS患者和有上拉喹莫德有效地治疗患者或减少卧床恶化量的高基线残疾评分。 本发明进一步提供药物组合物和产品的治疗诊断与RRMS折磨的人类患者和具有高基线残疾评分gemäß到EDSS包括有效量的拉喹莫德的的。

    TREATMENT OF CROHN'S DISEASE USING LOW DOSES OF LAQUINIMOD
    8.
    发明公开
    TREATMENT OF CROHN'S DISEASE USING LOW DOSES OF LAQUINIMOD 审中-公开
    治疗克罗恩病使用低剂量的拉喹莫德

    公开(公告)号：EP3094330A1

    公开(公告)日：2016-11-23

    申请号：EP15737558.5

    申请日：2015-01-15

    申请人： Teva Pharmaceutical Industries Ltd

    发明人： BROWN, Kurt, A. ,  SORANI, Ella

    IPC分类号： A61K31/47 ,  A61K31/4704 ,  A61P37/02

    CPC分类号： A61K31/4704 ,  A61K9/48

    摘要： This invention provides a method of treating a subject suffering from Crohn's disease, comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject, which amount of laquinimod is less than 0.5 mg/day, wherein the subject is naive to laquinimod and the administration continues for at least 12 weeks, or wherein the subject is being treated with another Crohn's disease therapy at baseline. Furthermore, this invention provides a corresponding therapeutic package, use of laquinimod or pharmaceutically acceptable salt thereof in the manufacture of a medicament, and pharmaceutical composition.